Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.91 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.91 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.91 |
| ▸ | NPC1 | O15118 | 1/20 | 0.91 |
| ▸ | RAB9A | P51151 | 1/20 | 0.91 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.71 |
| ▸ | CLK1 | P49759 | 2/20 | 0.71 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.71 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.71 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.62 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272567 | 1.00 | PIM1 (0.91) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL5509142 | 1.00 | PIM1 (0.91) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL2546911 | 0.95 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL1247708 | 0.95 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL1247705 | 0.95 | PIM1 (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL3796470 | 0.86 | AKR1B1 (0.67) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL3796472 | 0.86 | AKR1B1 (0.67) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL1249023 | 0.86 | HPGD (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL1249025 | 0.86 | HPGD (1.00) | PIM1PIM2AKR1B1NPC1RAB9A | |
| SCHEMBL1300557 | 0.86 | HPGD (1.00) | PIM1PIM2AKR1B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | claimed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | ESR2, ESRRG, GPER1 | PIM1 4500/4885PIM2 4143/4885AKR1B1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.